viewCellmid Limited

Cellmid enters exclusive distribution agreement for anti-ageing skincare product

Fillerina® is the first non-invasive filler treatment with clinical study results published in a peer-reviewed article.

Person looking through microscope
Fillerina is a world first, patented dermo-cosmetic filler treatment

Cellmid Limited (ASX:CDY) has entered into an agreement with Labo International S.r.l to undertake the exclusive distribution of Fillerina® in Australia and New Zealand for an initial period of up to five years.

The product is a market leading Swiss anti-ageing skincare brand and management expects that it will make a strong contribution to profits.

Under the terms of the agreement, joint distribution and sales targets will be established and there will be a close marketing collaboration between the parties.

World first treatment process

Fillerina is a world-first, patented dermo-cosmetic filler treatment.

It has been scientifically proven to reduce facial wrinkles, deliver measurable filling effects, increase facial volumes and decrease the clinical signs of skin ageing.

Fillerina is the first non-invasive filler treatment with clinical study results published in a peer-reviewed article.

First in class, best in class

Management noted that it is a market leader in innovative, high-performance skincare within the fast-growing anti-ageing cosmetics space globally.

Cellmid’s chief executive officer Maria Halasz said: “Our growth strategy for the Advangen subsidiary is focused on first in class, best in class, clinically validated anti-ageing products for hair, skin and body.

“Having built a successful distribution network for our FGF5 inhibitor hair products, Fillerina is an exciting addition to our consumer health business.”

This is reflected in the record sales growth being achieved by the FGF5 product.

READ: Cellmid achieves record quarterly sales for its hair care products

Cellmid’s addressable market continues to experience exceptional growth.

Anti-ageing cosmetics market to grow 24% by 2021

The anti-ageing cosmetics market is experiencing strong growth and according to Euromonitor 2017, it is predicted to expand a further 24% by 2021 in Australia.

Fillerina is complementary to the company’s evolis® haircare range with its innovative, patented technology.

Importantly, the Fillerina distribution agreement will generate efficiencies for Cellmid through the increased utilisation of the company’s existing evolis national sales and digital marketing team.

Fillerina to benefit from established marketing division

The established marketing division already has an extensive presence throughout major retail channels such as pharmacies, as well as e-commerce distribution.

Labo Cosprophar AG is Cellmid’s parent company and its chief executive officer Marcel Leutzelschwab said: “We are excited to partner with Advangen for the exclusive distribution of our Fillerina product range in Australia and New Zealand.

“We believe that our product philosophy is perfectly aligned to maximise the market potential for Fillerina, which has become the leading dermo-cosmetic filler in more than 40 countries worldwide since its launch in 2013.” 

Quick facts: Cellmid Limited

Price: 0.185 AUD

Market: ASX
Market Cap: $22.33 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from...



Cellmid Limited to supply rapid diagnostic tests to help in new pandemic

Cellmid Limited (ASX:CDY) CEO Maria Halasz tells Proactive's Andrew Scott they've signed an agreement to supply rapid diagnostic tests (RDT), with products expected to arrive in the country by early April. The test uses a virus-specific detection method that delivers results anywhere between...

on 30/3/20

3 min read